c‐Jun‐mediated JMJD6 restoration enhances resistance of liver cancer to radiotherapy through the IL‐4‐activated ERK pathway

Abstract

AbstractRadiotherapy is widely used in the treatment of liver cancer, but the efficacy can be limited by radioresistance. In this study, we attempt to delineate the possible molecular mechanism of c‐Jun‐regulated Jumonji domain‐containing protein 6/interleukin 4/extracellular signal‐regulated kinase (JMJD6/IL‐4/ERK) axis in radioresistance of liver cancer. The expression of c‐Jun was quantified in liver cancer tissues and cell lines, and the results indicated that c‐Jun was upregulated in liver cancer tissues and cells. We further illustrated the role of c‐Jun following gain‐ and loss‐of‐function strategies in malignant phenotypes of liver cancer cells. It was established that c‐Jun elevated JMJD6 expression and augmented the malignancy and aggressiveness of liver cancer cells. The in vivo effects of c‐Jun on radioresistance in liver cancer were validated in nude mice, in response to IL‐4 knockdown or the ERK pathway inhibitor, PD98059. In the presence of JMJD6 upregulation, the expression of IL‐4 was elevated in mice with liver cancer, which enhanced the radiation resistance. Moreover, knockdown of IL‐4 inactivated the ERK pathway, thereby reversing the radiation resistance caused by overexpressed JMJD6 in tumor‐bearing mice. Taken together, c‐Jun augments the radiation resistance in liver cancer by activating the ERK pathway through JMJD6‐upregulated IL‐4 transcription.